Talphera (TLPH) Gross Margin (2016 - 2023)

Talphera (TLPH) posted quarterly Gross Margin of 100.0% for Q3 2023, little changed quarter-over-quarter from 100.0% in Q2 2023.

Talphera (TLPH) Gross Margin (2016 - 2023) Analysis & Trends

Talphera's Gross Margin history runs 8 years deep, the most recent figure standing at 100.0% for Q3 2023.

In Q3 2023, Gross Margin changed N/A year-over-year to 100.0%; the TTM figure through Mar 2024 stood at 24.58% (up 50102.0% YoY), while the FY2021 annual figure was 33.18%, down 2181.0% from the prior year.
Gross Margin for Q3 2023 stood at 100.0%, roughly flat from 100.0% in the prior quarter.
The five-year high for Gross Margin was 100.0% in Q2 2023, with the low at 61600.0% in Q4 2021.
The 5-year median for Gross Margin is 84.25% (2019), against an average of 3931.24%.
The sharpest annual moves came in 2020 and 2021: Gross Margin soared 21798 bps in 2020, then sank 6152385 bps in 2021.
Talphera's Gross Margin stood at 240.63% in 2019, then soared by 68 bps to 76.15% in 2020, then sank by 80791 bps to 61600.0% in 2021, then surged by 100 bps to 6.33% in 2022, then surged by 1479 bps to 100.0% in 2023.
Business Quant data shows TLPH's Gross Margin at 100.0% in Q3 2023, 100.0% in Q2 2023, and 41.92% in Q1 2023.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Gross Margin (Qtr)
1	Haleon	43.89 Bn	42.93 Bn	-	-
2	Teva Pharmaceutical Industries	43.01 Bn	39.35 Bn	2.15 Bn	51.98%
3	Zoetis	31.52 Bn	29.84 Bn	1.05 Bn	42.63%
4	Takeda Pharmaceutical	28.61 Bn	22.81 Bn	5.10 Bn	66.66%
5	United Therapeutics	22.17 Bn	19.51 Bn	683.80 Mn	87.30%
6	Viatris	18.73 Bn	17.85 Bn	1.46 Bn	38.77%
7	Neurocrine Biosciences	15.51 Bn	15.12 Bn	935.80 Mn	97.58%
8	Elanco Animal Health	11.75 Bn	11.22 Bn	798.00 Mn	58.33%
9	Dr Reddys Laboratories	10.12 Bn	9.96 Bn	-	-
10	Talphera	89.88 Mn	89.88 Mn	-	-

Download Data